SINOMAB BIO-B (03681) announced that on March 24, 2026, the company granted 11.5748 million share options to two eligible individuals under the 2022 Share Option Scheme. These options grant the recipients the right to subscribe for a total of 11.5748 million new shares of the company, which will be effective upon acceptance by the recipients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.